{
  "source": "PA-Notification-Venclexta.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1186-10\nProgram Prior Authorization/Notification\nMedication Venclexta® (venetoclax)\nP&T Approval Date 5/2016, 5/2017, 5/2018, 4/2019, 4/2020, 4/2021, 4/2022, 4/2023, 4/2024,\n4/2025\nEffective Date 7/1/2025\n1. Background:\nVenclexta (venetoclax) is a BCL-2 inhibitor indicated for the treatment of adult patients with\nchronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Venclexta is also\nindicated in combination with azacitidine, or decitabine, or low-dose cytarabine for the\ntreatment of newly diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or\nolder, or who have comorbidities that preclude use of intensive induction chemotherapy.\nIn addition, the National Cancer Comprehensive Network (NCCN) recommends the use of\nVenclexta in acute lymphoblastic leukemia (ALL); in newly diagnosed, relapsed/refractory, and\nblastic plasmacytoid dendritic cell neoplasm (BPDCN) AML; relapsed/refractory hairy cell\nleukemia; mantle cell lymphoma as second line or subsequent therapy; in relapsed or\nprogressive multiple myeloma with t(11;14) translocation; for relapsed/refractory systemic light\nchain amyloidosis with t(11;14) translocation; in previously treated Waldenstrom\nmacroglobulinemia/lymphoplasmacytic lymphoma; in accelerated/blast phase\nmyeloproliferative neoplasm (MPN) with disease progression; in chronic myelomonocytic\nleukemia (CMML); and in higher risk myelodysplastic syndromes.\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the age\nof 19 years, the prescription will automatically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or\nunder some circumstances. Some states also mandate usage of other Compendium references.\nWhere such mandates apply, they supersede language in the benefit document or in the\nnotification criteria.\n2. Coverage C",
    " circumstances. Some states also mandate usage of other Compendium references.\nWhere such mandates apply, they supersede language in the benefit document or in the\nnotification criteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Venclexta will be approved based on the following criterion:\na. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Acute Lymphoblastic Leukemia (ALL)\n1. Initial Authorization\n© 2025 UnitedHealthcare Services, Inc.\n1\na. Venclexta will be approved based on both of the following criteria:\n(1) Diagnosis of relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL)\n-AND-\n(2) Venclexta therapy to be given in combination with one of the following:\n(a) Decitabine\n(b) HyperCVAD\n(c) Nelarabine\n(d) Mini-hyperCVD\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Venclexta will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Venclexta therapy\nAuthorization will be issued for 12 months.\nC. Acute Myeloid Leukemia (AML)\n1. Initial Authorization\na. Venclexta will be approved based on one of the following criteria:\n(1) All of the following:\n(a) Diagnosis of newly-diagnosed acute myeloid leukemia (AML)\n-AND-\n(b) One of the following:\ni. Used as treatment induction in candidates for intensive induction therapy\nii. Used as treatment induction in candidates for lower-intensity induction\ntherapy\niii. Used as follow-up after induction therapy following response to previous\nlower intensity therapy with the same regimen\niv. Used as consolidation therapy as continuation of lower-intensity regimen\nused for induction\n-AND-\n© 2025 UnitedHealthcare Services, Inc.\n2\n(c) Used in combination with decitabine, azacitidine, or low-dose cytarabine\n-OR-\n(2) All of the following:\n(a) Diagnosis of relapsed/refractory acute myeloid leukemia (AML)\n-AND-\n(b) Used as a component of repeating the initial successful induction regimen\n-AND-\n(c) Great",
    "ine\n-OR-\n(2) All of the following:\n(a) Diagnosis of relapsed/refractory acute myeloid leukemia (AML)\n-AND-\n(b) Used as a component of repeating the initial successful induction regimen\n-AND-\n(c) Greater than or equal to 12 months since induction regimen if not administered\ncontinuously\n-AND-\n(d) Therapy was not stopped due to development of clinical resistance\n-OR-\n(3) All of the following:\n(a) Diagnosis of blastic plasmacytoid dendritic cell neoplasm (BPDCN) - acute\nmyeloid leukemia (AML)\n-AND-\n(b) Considered systemic disease and therapy is given as palliative intent\n-AND-\n(c) Patient has low performance and/or nutritional status (i.e., serum albumin <3.2\ng/dL; not a candidate for intensive remission therapy or Elzonris)\n-AND-\n(d) Venclexta therapy to be given in combination with azacitidine, decitabine, or\nlow-dose cytarabine\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Venclexta will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Venclexta therapy\n© 2025 UnitedHealthcare Services, Inc.\n3\nAuthorization will be issued for 12 months.\nD. Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)\n1. Initial Authorization\na. Venclexta will be approved based on the following criterion:\n(1) Diagnosis of chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma\n(SLL)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Venclexta will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Venclexta therapy\nAuthorization will be issued for 12 months.\nE. Chronic Myelomonocytic Leukemia (CMML)\n1. Initial Authorization\na. Venclexta will be approved based on all the following criteria:\n(1) Diagnosis of chronic myelomonocytic leukemia (CMML)\n-AND-\n(2) Classified as CMML-2 (less than 20% bone marrow blasts or blast equivalents)\n-AND-\n(3) Venclexta therapy to be given in combination with azacitidine or decitabine",
    "lomonocytic leukemia (CMML)\n-AND-\n(2) Classified as CMML-2 (less than 20% bone marrow blasts or blast equivalents)\n-AND-\n(3) Venclexta therapy to be given in combination with azacitidine or decitabine\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Venclexta will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Venclexta therapy\nAuthorization will be issued for 12 months.\nF. Hairy Cell Leukemia\n1. Initial Authorization\n© 2025 UnitedHealthcare Services, Inc.\n4\na. Venclexta will be approved based on all of the following criteria:\n(1) Diagnosis of hairy cell leukemia\n-AND-\n(2) Disease is progressive after relapsed/refractory therapy\n-AND-\n(3) Disease is resistant to BRAF inhibitor therapy (i.e., Zelboraf, Tafinlar)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Venclexta will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Venclexta therapy\nAuthorization will be issued for 12 months.\nG. Mantle Cell Lymphoma\n1. Initial Authorization\na. Venclexta will be approved based on both of the following criteria:\n(1) Diagnosis of mantle cell lymphoma (MCL)\n-AND-\n(2) Not used as first line therapy\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Venclexta will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Venclexta therapy\nAuthorization will be issued for 12 months.\nH. Multiple Myeloma\n1. Initial Authorization\na. Venclexta will be approved based on all of the following criteria:\n© 2025 UnitedHealthcare Services, Inc.\n5\n(1) Diagnosis of relapsed or progressive multiple myeloma which has been previously\ntreated\n-AND-\n(2) Patient has t(11;14) translocation\n-AND-\n(3) Venclexta therapy to be given in combination with one of the following:\ni. dexamethasone\nii. dexamethasone and daratumumab\niii. dexamethasone and either bortezomib, carfilzomib",
    "translocation\n-AND-\n(3) Venclexta therapy to be given in combination with one of the following:\ni. dexamethasone\nii. dexamethasone and daratumumab\niii. dexamethasone and either bortezomib, carfilzomib, or ixazomib\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Venclexta will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Venclexta therapy\nAuthorization will be issued for 12 months.\nI. Myeloproliferative Neoplasms – Accelerated/Blast Phase Myeloproliferative Neoplasms\n1. Initial Authorization\na. Venclexta will be approved based on all of the following criteria:\n(1) Diagnosis of accelerated/blast phase myeloproliferative neoplasm\n-AND-\n(2) Used for management of disease progression of myeloproliferative neoplasm\n-AND-\n(3) Venclexta therapy to be given in combination with azacitidine or decitabine\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Venclexta will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Venclexta therapy\n© 2025 UnitedHealthcare Services, Inc.\n6\nAuthorization will be issued for 12 months.\nJ. Systemic Light Chain Amyloidosis\n1. Initial Authorization\na. Venclexta will be approved based on both of the following criteria:\n(1) Diagnosis of relapsed/refractory systemic light chain amyloidosis\n-AND-\n(2) Patient has t(11;14) translocation\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Venclexta will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Venclexta therapy\nAuthorization will be issued for 12 months.\nK. Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma\n1. Initial Authorization\na. Venclexta will be approved based on the following criterion:\n(1) Diagnosis of Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma\nwhich has been previously treated\nAuthorization will be issued for 12 months.\n2. Reaut",
    "roved based on the following criterion:\n(1) Diagnosis of Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma\nwhich has been previously treated\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Venclexta will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Venclexta therapy\nAuthorization will be issued for 12 months.\nL. Myelodysplastic Syndromes\n1. Initial Authorization:\na. Venclexta will be approved based on all of the following criteria:\n(1) Disease is higher risk (IPSS-R Intermediate, High, or Very High)\n© 2025 UnitedHealthcare Services, Inc.\n7\n-AND-\n(2) Used as initial treatment\n-AND-\n(3) Used in combination with azacitidine or decitabine\nAuthorization will be issued for 12 months\n2. Reuthorization:\na. Venclexta will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Venclexta\nAuthorization will be issued for 12 months\nM. NCCN Recommended Regimens\nThe drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a Category\nof Evidence and Consensus of 1, 2A, or 2B\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class\n• Supply limits may be in place.\n4. References:\n1. Venclexta [package insert]. North Chicago, IL: AbbVie Inc. June 2022.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nhttp://www.nccn.",
    "ts may be in place.\n4. References:\n1. Venclexta [package insert]. North Chicago, IL: AbbVie Inc. June 2022.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nhttp://www.nccn.org/professionals/drug_compendium/content/contents.asp. Accessed March\n13, 2025.\nProgram Prior Authorization/Notification - Venclexta (venetoclax)\nChange Control\n5/2016 New program approved by FDA on 4/11/2016. Added SLL to criteria\nper NCCN. Updated background and references.\n© 2025 UnitedHealthcare Services, Inc.\n8\n5/2017 Annual review. Removed requirement for 17p deletion or TP53\nmutation for CLL/SLL and added criteria for MCL per NCCN\nguidelines. Updated references.\n5/2018 Annual review. No changes to criteria. Updated references.\n4/2019 Annual review. Added coverage for AML based on prescribing\ninformation and NCCN guidelines. Updated references.\n4/2020 Annual review. Updated background and criteria to align with updated\nlabeled indication for first line use in CLL/SLL. Added general NCCN\nrecommendations for use criteria. Updated references.\n4/2021 Annual review. Updated background and criteria for multiple myeloma\nbased on NCCN recommendations. Updated references.\n4/2022 Annual review. Updated background and criteria to include acute\nlymphoblastic leukemia, systemic light chain amyloidosis, and\nWaldenstrom macroglobulinemia/lymphoplasmacytic lymphoma based\non NCCN recommendations. Updated references.\n4/2023 Annual review. Updated background. Specified Ph-neg disease in ALL.\nAdded additional AML recommendations. Added state mandate and\noncology medications footnote. Updated references.\n4/2024 Annual review. Updated background on NCCN recommendations.\nUpdated criteria for ALL and AML based on NCCN recommendations.\nAdded criteria for additional indications based on NCCN\nrecommendations for the following: hairy cell leukemia,\nmyeloproliferative neoplasms – accelerated/blast phase\nmyeloproliferative neoplasms, and CMML. Removed oncology\nmedications footnote.\n4/2025 Ann",
    "recommendations for the following: hairy cell leukemia,\nmyeloproliferative neoplasms – accelerated/blast phase\nmyeloproliferative neoplasms, and CMML. Removed oncology\nmedications footnote.\n4/2025 Annual review. Updated background and criteria to include\nMyelodysplastic Syndromes based on NCCN recommendations.\nUpdated multiple myeloma criteria to include additional drugs to be\ngiven in combinations with. Updated references.\n© 2025 UnitedHealthcare Services, Inc.\n9"
  ]
}